← ORMP
ORMP— ORAMED PHARMACEUTICALS INC.
| Metric | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|
| REVENUES | $1.3M-50.4% | $2.7M+0.0% | $2.7M-0.3% | $2.7M |
| RESEARCH AND DEVELOPMENT EXPENSES | -$9.0M+67.5% | -$27.6M-231.7% | $21.0M+105.1% | $10.2M |
| SALES AND MARKETING | $287K+115.5% | -$1.9M-200.0% | $1.9M | — |
| GENERAL AND ADMINISTRATIVE EXPENSES | -$8.4M+39.0% | -$13.8M-332.6% | $5.9M+40.3% | $4.2M |
| OPERATING LOSS | -$15.8M+61.2% | -$40.6M-267.6% | $24.2M+106.0% | $11.8M |
| INTEREST EXPENSES (note 11b) | -$2.0M | — | — | — |
| FINANCIAL INCOME (EXPENSES), NET (note 11a) | $22.9M+680.3% | $2.9M | — | — |
| INCOME (LOSS) BEFORE TAX EXPENSES | $5.1M+113.5% | -$37.7M | — | — |
| TAX EXPENSES | -$100K | — | — | — |
| NET LOSS (INCOME) | $5.1M+113.5% | -$37.8M-264.3% | $23.0M | — |
| COMPANY’S STOCKHOLDERS | $5.5M+115.1% | -$36.6M-264.4% | $22.2M+93.2% | $11.5M |
| NON-CONTROLLING INTERESTS | -$437K+63.7% | -$1.2M-260.2% | $751K | — |
| NET INCOME (LOSS) | $5.1M+113.5% | -$37.8M-264.3% | $23.0M | — |
| BASIC INCOME (LOSS) PER SHARE OF COMMON STOCK (in Dollars per share) | $140+114.9% | -$940-220.5% | $780 | — |
| DILUTED INCOME (LOSS) PER SHARE OF COMMON STOCK (in Dollars per share) | $140+114.9% | -$940 | — | — |
| WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK USED IN COMPUTING BASIC INCOME (LOSS) PER SHARE OF COMMON STOCK (in Shares) | $40.32B+3.4% | $39.00B+37.0% | $28.47B | — |
| WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK USED IN COMPUTING DILUTED INCOME (LOSS) PER SHARE OF COMMON STOCK (in Shares) | $40.57B+4.0% | $39.00B | — | — |
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
Source: SEC EDGAR 10-K and 10-Q filings. Up to 10 years annual / 16 quarters shown.